Harpula
Jack Shannon has a diverse and extensive work experience in the commercial and business development roles. Jack started their career at Quintiles in 2001 in a sales position and worked there until 2008. Jack then joined PRA International and held various positions, including Account Director, Director of Business Development, and Senior Director of Business Development. In 2013, they became the Executive Director of Business Development, managing strategic accounts and leading the North American Inside Sales Team. In 2014, they joined Chiltern as the Vice President of Global Business Development BioPharma, where they mentored and managed a sales team and handled a diverse account portfolio. Jack then moved to Synteract in 2017, initially serving as the Chief Commercial Officer and later as the Executive Vice President of Business Development & Marketing. Jack joined Virb, Inc. in 2022 as the Chief Commercial Officer before moving to their current role as the Chief Commercial Officer of Harpula in 2023.
Jack Shannon attended the New York Institute of Technology from 2005 to 2007, where they obtained a Master of Business Administration (M.B.A.) degree in Business.
This person is not in any teams
Harpula
Harpula was formed to foster the growth of next generation technology and services for clinical trials. Our goal is to build a company that excels in today’s clinical trial landscape of personalized medicine, multiple trial modalities, and increased patient centricity. Harpula builds on the founders’ years of experience in clinical trial execution and technology. We recognize the opportunity to build a more coordinated technology solution through acquisition and organic growth. We seek to invest in companies and assets in the technology-enabled pharmaceutical solutions industry to improve the clinical trial experience for patients, sites, and sponsors. Technology solutions have had a tremendously positive impact on the quality and efficiency of clinical trials. As the number and type of solutions have propagated, the burden on sponsors, sites, and patients has increased. There is opportunity to consolidate platforms to address critical pain points around the patient and site experience and ultimately deliver drugs to patients faster.